로그인 회원가입
icon_bulk_order대량 주문 조회 Acrobiosystems for English
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: > Fusion glycoprotein F0

Fusion glycoprotein F0

요약

Name:Respiratory syncytial virus F protein
Target Synonym:Protein F,F,Fusion glycoprotein F0
Number of Launched Drugs:2
Number of Drugs in Clinical Trials:5
Lastest Research Phase:Approved

제품 리스트 비교 또는 구매

제품 상태별:
제품 유형별 :
태그별:
제품번호 제품 설명 구조 순도 특징
RSF-V52H6 Human respiratory syncytial virus A (strain A2) HRSV (A) Post-fusion glycoprotein F0, His Tag (MALS verified)
RSF-V52H6-sds
RSF-V52H7 Human respiratory syncytial virus A (strain A2) HRSV (A) Pre-fusion glycoprotein F0, His Tag
RSF-V52H7-sds

일부의 생물활성 데이터

RSF-V52H7-ELISA
 Fusion glycoprotein F0 ELISA

Immobilized HRSV (A) Fusion glycoprotein F0, His Tag (Cat. No. RSF-V52H7) at 2 μg/mL (100 μL/well) can bind Anti-Fusion glycoprotein F0 Antibody, Human IgG1 (D25) with a linear range of 0.2-1 ng/mL (QC tested).

RSF-V52H6-MALS-HPLC
Fusion glycoprotein F0 MALS images

The purity of HRSV (A) Fusion glycoprotein F0, His Tag(Cat. No. RSF-V52H6) is more than 90% and the molecular weight of this protein is around 148-182kDa verified by SEC-MALS.

Synonym Name

Fusion glycoprotein F0

Background

Human respiratory syncytial virus (HRSV) is the most common etiological agent of acute lower respiratory tract disease in infants and can cause repeated infections throughout life. The RSV fusion glycoprotein (RSV F) is the principal target of RSV neutralizing antibodies in human sera. The RSV F is a type I viral fusion protein synthesized as inactive, single-chain polypeptides that assemble into trimers. RSV F fuses the viral and host cell membranes by irreversible protein refolding from the labile prefusion conformation to the stable post-fusion conformation. Both states exhibit epitopes targeted by neutralizing antibodies, and post-fusion RSV F is being developed as a vaccine candidate.

Clinical and Translational Updates

공개 약품 정보

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Respiratory syncytial virus immune globulin RSV-IGIV Approved Medimmune RespiGam Canada Respiratory Syncytial Virus Infections Medimmune Llc 1996-01-01 Respiratory Syncytial Virus Infections Details
Palivizumab ABT-315; MEDI-493 Approved Abbvie Inc, Medimmune Llc Synagis Japan Respiratory Syncytial Virus Infections Abbvie Inc 1998-06-19 Bronchopulmonary Dysplasia; Respiratory Syncytial Virus Infections; Heart Defects, Congenital; Infant, Premature, Diseases; Premature Birth Details

임상 약품 정보

Name Research Code Research Phase Company Indications Clinical Trials
Motavizumab biosimilar (MedImmune) MEDI-557 Medimmune Llc Details
Motavizumab MEDI-524 Medimmune Llc Details
Suptavumab H1H3592P3; REGN-2222; SAR-438584; A0ZE931055 (UNII code) Regeneron Pharmaceuticals Inc, Sanofi Details
Nirsevimab Anti-RSV-mAb-D25; SP-0232; MEDI-8897; Anti-RSV MAb-YTE Phase 3 Clinical Aimm Therapeutics, Sanofi Respiratory Syncytial Virus Infections Details
Ziresovir AK-0529; RO-0529 Phase 3 Clinical F. Hoffmann-La Roche Ltd Respiratory Syncytial Virus Infections Details
CPI-RSV-F Vaccine BLB-201 Phase 1 Clinical Respiratory Syncytial Virus Infections Details

This web search service is supported by Google Inc.

totop